About: Pemigatinib

Property	Value
dbo:abstract	Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading. Pemigatinib belongs to a group of medicines called protein kinase inhibitors. It works by blocking enzymes known as protein kinases, particularly those that are part of receptors (targets) called fibroblast growth factor receptors (FGFRs). FGFRs are found on the surface of cancer cells and are involved in the growth and spread of the cancer cells. By blocking the tyrosine kinases in FGFRs, pemigatinib is expected to reduce the growth and spread of the cancer. The most common adverse reactions are hyperphosphatemia and hypophosphatemia (electrolyte disorders), alopecia (spot baldness), diarrhea, nail toxicity, fatigue, dysgeusia (taste distortion), nausea, constipation, stomatitis (sore or inflammation inside the mouth), dry eye, dry mouth, decreased appetite, vomiting, joint pain, abdominal pain, back pain and dry skin. Ocular (eye) toxicity is also a risk of pemigatinib. Additional common adverse reactions include rash, anemia, epistaxis, serous retinal detachment, extremity pain, dyspepsia, blurred vision, peripheral edema, and dizziness. (en) ペミガチニブ（Pemigatinib）は、に分類される胆管癌治療薬である。タンパク質キナーゼとして知られる酵素、特に癌細胞の表面に存在し増殖や転移に関与する線維芽細胞増殖因子受容体（FGFR）の一部を構成するチロシンキナーゼの阻害によって作用する。 FDA承認の臨床検査で検出された（FGFR2）の融合またはその他の再配列を有する、前治療歴のある切除不能な局所進行性または転移性胆管癌の成人患者を対象とする。 (ja)
dbo:alternativeName	Pemazyre (en)
dbo:casNumber	1513857-77-6
dbo:chEMBL	4297522
dbo:drugbank	DB15102
dbo:fdaUniiCode	Y6BX7BL23K
dbo:kegg	D11417
dbo:medlinePlus	a620028
dbo:pubchem	86705695
dbo:thumbnail	wiki-commons:Special:FilePath/Pemigatinib.svg?width=300
dbo:wikiPageExternalLink	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pemigatinib https://druginfo.nlm.nih.gov/drugportal/name/pemigatinib
dbo:wikiPageID	63691273 (xsd:integer)
dbo:wikiPageLength	18694 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1115585615 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Priority_review dbr:Indication_(medicine) dbr:International_nonproprietary_name dbr:Alopecia dbr:Stomatitis dbr:Oral_administration dbr:Orphan_drug dbr:Protein_kinase_inhibitors dbr:Protein_kinases dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:Fatigue dbc:Orphan_drugs dbr:Dysgeusia dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Foundation_Medicine dbr:Breakthrough_therapy dbr:Hyperphosphatemia dbr:Hypophosphatemia dbc:Breakthrough_therapy dbc:Receptor_tyrosine_kinase_inhibitors dbr:Bile_duct_cancer dbr:Anti-cancer_medication
dbp:atcPrefix	L01 (en)
dbp:atcSuffix	EN02 (en)
dbp:c	24 (xsd:integer)
dbp:casNumber	1513857 (xsd:integer)
dbp:chembl	4297522 (xsd:integer)
dbp:chemspiderid	68007304 (xsd:integer)
dbp:dailymedid	Pemigatinib (en)
dbp:drugbank	DB15102 (en)
dbp:f	2 (xsd:integer)
dbp:h	27 (xsd:integer)
dbp:iupacName	180.0
dbp:kegg	D11417 (en)
dbp:legalAu	S4 (en)
dbp:legalCa	Rx-only (en)
dbp:legalEu	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:licenceEu	yes (en)
dbp:medlineplus	a620028 (en)
dbp:n	5 (xsd:integer)
dbp:o	4 (xsd:integer)
dbp:pregnancyAu	D (en)
dbp:pubchem	86705695 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:smiles	CCN1C2=C3C=CCN5CCOCC5 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	HCDMJFOHIXMBOV-UHFFFAOYSA-N (en)
dbp:synonyms	INCB054828 (en)
dbp:tradename	Pemazyre (en)
dbp:unii	Y6BX7BL23K (en)
dbp:wikiPageUsesTemplate	dbt:Cite_journal dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:Growth_factor_receptor_modulators dbt:ClinicalTrialsGov dbt:Targeted_cancer_therapeutic_agents
dcterms:subject	dbc:Orphan_drugs dbc:Breakthrough_therapy dbc:Receptor_tyrosine_kinase_inhibitors
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	ペミガチニブ（Pemigatinib）は、に分類される胆管癌治療薬である。タンパク質キナーゼとして知られる酵素、特に癌細胞の表面に存在し増殖や転移に関与する線維芽細胞増殖因子受容体（FGFR）の一部を構成するチロシンキナーゼの阻害によって作用する。 FDA承認の臨床検査で検出された（FGFR2）の融合またはその他の再配列を有する、前治療歴のある切除不能な局所進行性または転移性胆管癌の成人患者を対象とする。 (ja) Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading. (en)
rdfs:label	ペミガチニブ (ja) Pemigatinib (en)
owl:sameAs	wikidata:Pemigatinib dbpedia-ja:Pemigatinib dbpedia-tr:Pemigatinib https://global.dbpedia.org/id/C4Uye
prov:wasDerivedFrom	wikipedia-en:Pemigatinib?oldid=1115585615&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Pemigatinib.svg
foaf:isPrimaryTopicOf	wikipedia-en:Pemigatinib
is dbo:wikiPageRedirects of	dbr:Pemazyre
is dbo:wikiPageWikiLink of	dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Pemazyre dbr:ATC_code_L01 dbr:Cholangiocarcinoma dbr:Incyte
is foaf:primaryTopic of	wikipedia-en:Pemigatinib